EFFECT OF CILOSTAZOL ON ENDOTHELIAL PROGENITOR CELLS AND HYBRID THERAPY IN MURINE HINDLIMB ISCHEMIA  by Chao, Ting-Hsing et al.
E1481
JACC April 5, 2011
Volume 57, Issue 15
  VASCULAR DISEASE
EFFECT OF CILOSTAZOL ON ENDOTHELIAL PROGENITOR CELLS AND HYBRID THERAPY IN MURINE 
HINDLIMB ISCHEMIA
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 3:30 p.m.-4:45 p.m.
Session Title: Cell Therapy and Cardiovascular Diseases
Abstract Category: 9. Vascular—Pathophysiology—Basic/Angiogenesis/Gene Therapy
Session-Poster Board Number: 1042-112
Authors: Ting-Hsing Chao, Shih-Ya Tseng, Yi-Heng Li, Guey-Yueh Shi, Hua-Lin Wu, Jyh-Hong Chen, National Cheng Kung University College of Medicine 
and Hospital and Dou-Liou Branch, Tainan and Yun-Lin, Taiwan, ROC
Background:  We and others have reported that cilostazol could promote angiogenesis. In this study, we investigated the effects of cilostazol on 
endothelial progenitor cells (EPCs) and hybrid therapy in murine hindlimb ischemia.
Methods:  Cilostazol was added 3 days after isolation and culture of human early EPCs. Colony-forming units were counted 7 days later. Total 
ribonucleic acid was extracted from EPCs treated with cilostazol and subjected to reverse transcription-polymerase chain reaction analysis of 
endothelial NO synthase (eNOS), vascular endothelial growth factor-receptor 2 (VEGF-R2), and CD31. Eight-week-old male SCID mice were divided 
into 4 groups (vehicle, EPCs only, cilostazol only, and EPCs plus cilostazol, respectively). 1×106 of culture-expanded EPCs were transplanted by 
multiple intramuscular injections one day after hindlimb ischemia. Single doses of cilostazol (10 mg/kg) were injected intraperitoneally before 
hindlimb ischemia and 2 times per day for 7 days.
Results:  Cilostazol (30 μM) treatment significantly increased colony-forming units of EPCs by 2.5 folds (25.2±0.9 vs 10.8±0.5 cells/well, p<0.05) 
and expression of eNOS, VEGF-R2, and CD31 as compared to negative control. Blood flow recovery ratio and capillary density after 14 days in 
the ischemic hindlimb were highest in EPCs plus cilostazol-treated mice (0.68±0.09; 3588±78 particles/mm2) than cilostazol only (0.48±0.01; 
2991±49 particles/mm2), EPCs only (0.35±0.03; 2788±49 particles/mm2), and vehicle (0.21±0.02; 2010±11 particles/mm2, all p<0.05 vs 
vehicle, respectively), which were attenuated by an eNOS inhibitor injection. Hybrid therapy had the upmost effect on phosphorylation of eNOS 
and Akt in ischemic muscle. Human CD31+ cells were mostly located around but far from host capillaries in EPCs only; however, they formed more 
capillaries with host endothelial cells in hybrid therapy.
Conclusions:  Cilostazol has significantly beneficial effect on endothelial differentiation in EPCs. It promotes vasculogensis of transplanted 
human EPCs in murine hindlimb ischemia partly mediated by activating Akt/eNOS signaling pathway and enhancing incorporation of EPCs into 
neovascularization site.
